Funding round completed
Moberg Derma AB completed a financing of SEK 27.7 million (about €3 millionin a round led by the Baltic Sea Foundation (Östersjöstiftelsen) with other institutional and private investors, as well as members of management.
“The newly raised fund will allow us to start a phase III trial in September for K101, a novel topical treatment for onychomycosis (nail fungus),” said Peter Wolpert, CEO. “It will also help us to meet our goal of having two products in late-stage clinical development by the end of this year.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.